Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 430

1.

Liver Transplant for Hepatocellular Carcinoma in the United States: Evolving Trends over the Last Three Decades.

Puigvehí M, Hashim D, Haber PK, Dinani A, Schiano TD, Asgharpour A, Kushner T, Kakked G, Tabrizian P, Schwartz M, Gurakar A, Dieterich D, Boffetta P, Friedman SL, Llovet JM, Saberi B.

Am J Transplant. 2019 Aug 22. doi: 10.1111/ajt.15576. [Epub ahead of print]

PMID:
31437349
2.

Publisher Correction: SOX9 regulated matrix proteins are increased in patients serum and correlate with severity of liver fibrosis.

Athwal VS, Pritchett J, Martin K, Llewellyn J, Scott J, Harvey E, Zaitoun AM, Mullan AF, Zeef LAH, Friedman SL, Irving WL, Hanley NA, Guha IN, Piper Hanley K.

Sci Rep. 2019 Aug 6;9(1):11547. doi: 10.1038/s41598-019-47715-2.

3.

An Immune Gene Expression Signature Associated With Development of Human Hepatocellular Carcinoma Identifies Mice That Respond to Chemopreventive Agents.

Moeini A, Torrecilla S, Tovar V, Montironi C, Andreu-Oller C, Peix J, Higuera M, Pfister D, Ramadori P, Pinyol R, Solé M, Heikenwälder M, Friedman SL, Sia D, Llovet JM.

Gastroenterology. 2019 Jul 22. pii: S0016-5085(19)41121-9. doi: 10.1053/j.gastro.2019.07.028. [Epub ahead of print]

PMID:
31344396
4.

Mannose Phosphate Isomerase and Mannose Regulate Hepatic Stellate Cell Activation and Fibrosis in Zebrafish and Humans.

DeRossi C, Bambino K, Morrison J, Sakarin I, Villacorta-Martin C, Zhang C, Ellis JL, Fiel MI, Ybanez M, Lee YA, Huang KL, Yin C, Sakaguchi TF, Friedman SL, Villanueva A, Chu J.

Hepatology. 2019 Apr 23. doi: 10.1002/hep.30677. [Epub ahead of print]

PMID:
31016744
5.

SOX9 regulated matrix proteins are increased in patients serum and correlate with severity of liver fibrosis.

Athwal VS, Pritchett J, Martin K, Llewellyn J, Scott J, Harvey E, Zaitoun AM, Mullan AF, Zeef LAH, Friedman SL, Irving WL, Hanley NA, Guha IN, Piper Hanley K.

Sci Rep. 2018 Dec 17;8(1):17905. doi: 10.1038/s41598-018-36037-4. Erratum in: Sci Rep. 2019 Aug 6;9(1):11547.

6.

Autophagy is a gatekeeper of hepatic differentiation and carcinogenesis by controlling the degradation of Yap.

Lee YA, Noon LA, Akat KM, Ybanez MD, Lee TF, Berres ML, Fujiwara N, Goossens N, Chou HI, Parvin-Nejad FP, Khambu B, Kramer EGM, Gordon R, Pfleger C, Germain D, John GR, Campbell KN, Yue Z, Yin XM, Cuervo AM, Czaja MJ, Fiel MI, Hoshida Y, Friedman SL.

Nat Commun. 2018 Nov 23;9(1):4962. doi: 10.1038/s41467-018-07338-z.

7.

Impaired endothelial autophagy promotes liver fibrosis by aggravating the oxidative stress response during acute liver injury.

Ruart M, Chavarria L, Campreciós G, Suárez-Herrera N, Montironi C, Guixé-Muntet S, Bosch J, Friedman SL, Garcia-Pagán JC, Hernández-Gea V.

J Hepatol. 2019 Mar;70(3):458-469. doi: 10.1016/j.jhep.2018.10.015. Epub 2018 Oct 25.

8.

A small molecule fibrokinase inhibitor in a model of fibropolycystic hepatorenal disease.

Paka P, Huang B, Duan B, Li JS, Zhou P, Paka L, Yamin MA, Friedman SL, Goldberg ID, Narayan P.

World J Nephrol. 2018 Sep 7;7(5):96-107. doi: 10.5527/wjn.v7.i5.96.

9.

Corrigendum to "A simple diet- and chemical-induced murine NASH model with rapid progression of steatohepatitis, fibrosis and liver cancer" [J Hepatol 69 (2018) 385-395].

Tsuchida T, Lee YA, Fujiwara N, Ybanez M, Allen B, Martins S, Isabel Fiel M, Goossens N, Chou HI, Hoshida Y, Friedman SL.

J Hepatol. 2018 Oct;69(4):988. doi: 10.1016/j.jhep.2018.07.010. Epub 2018 Aug 3. No abstract available.

PMID:
30082074
10.

Mechanisms of NAFLD development and therapeutic strategies.

Friedman SL, Neuschwander-Tetri BA, Rinella M, Sanyal AJ.

Nat Med. 2018 Jul;24(7):908-922. doi: 10.1038/s41591-018-0104-9. Epub 2018 Jul 2. Review.

11.

Clarity and Challenges in Tissue Fibrosis.

Friedman SL.

In: Nakao K, Minato N, Uemoto S, editors. Innovative Medicine: Basic Research and Development [Internet]. Tokyo: Springer; 2015.

12.

A Sabbatical: The Gift That Keeps on Giving.

Friedman SL.

Cell Mol Gastroenterol Hepatol. 2018 Feb 3;5(4):656-658. doi: 10.1016/j.jcmgh.2018.01.010. eCollection 2018. No abstract available.

13.

Slit2-Robo2 signaling modulates the fibrogenic activity and migration of hepatic stellate cells.

Zeng Z, Wu Y, Cao Y, Yuan Z, Zhang Y, Zhang DY, Hasegawa D, Friedman SL, Guo J.

Life Sci. 2018 Jun 15;203:39-47. doi: 10.1016/j.lfs.2018.04.017. Epub 2018 Apr 13.

14.

A pilot study of ultra-deep targeted sequencing of plasma DNA identifies driver mutations in hepatocellular carcinoma.

Labgaa I, Villacorta-Martin C, D'Avola D, Craig AJ, von Felden J, Martins-Filho SN, Sia D, Stueck A, Ward SC, Fiel MI, Mahajan M, Tabrizian P, Thung SN, Ang C, Friedman SL, Llovet JM, Schwartz M, Villanueva A.

Oncogene. 2018 Jul;37(27):3740-3752. doi: 10.1038/s41388-018-0206-3. Epub 2018 Apr 9.

15.

A simple diet- and chemical-induced murine NASH model with rapid progression of steatohepatitis, fibrosis and liver cancer.

Tsuchida T, Lee YA, Fujiwara N, Ybanez M, Allen B, Martins S, Fiel MI, Goossens N, Chou HI, Hoshida Y, Friedman SL.

J Hepatol. 2018 Aug;69(2):385-395. doi: 10.1016/j.jhep.2018.03.011. Epub 2018 Mar 21. Erratum in: J Hepatol. 2018 Oct;69(4):988.

16.

Altered global microRNA expression in hepatic stellate cells LX-2 by angiotensin-(1-7) and miRNA-1914-5p identification as regulator of pro-fibrogenic elements and lipid metabolism.

de Oliveira da Silva B, Alberici LC, Ramos LF, Silva CM, da Silveira MB, Dechant CRP, Friedman SL, Sakane KK, Gonçalves LR, Moraes KCM.

Int J Biochem Cell Biol. 2018 May;98:137-155. doi: 10.1016/j.biocel.2018.02.018. Epub 2018 Mar 7.

17.

Ligand-Dependent Corepressor (LCoR) Is a Rexinoid-Inhibited Peroxisome Proliferator-Activated Receptor γ-Retinoid X Receptor α Coactivator.

Shalom-Barak T, Liersemann J, Memari B, Flechner L, Devor CE, Bernardo TM, Kim S, Matsumoto N, Friedman SL, Evans RM, White JH, Barak Y.

Mol Cell Biol. 2018 Apr 16;38(9). pii: e00107-17. doi: 10.1128/MCB.00107-17. Print 2018 May 1.

18.

Megatrends in bile acid receptor research.

Adorini L, Schoonjans K, Friedman SL.

Hepatol Commun. 2017 Aug 24;1(8):831-835. doi: 10.1002/hep4.1085. eCollection 2017 Oct. No abstract available.

19.

Use of Transition Resources by Primary Care Providers for Youth With Intellectual and Developmental Disabilities.

Dressler PB, Nguyen TK, Moody EJ, Friedman SL, Pickler L.

Intellect Dev Disabil. 2018 Feb;56(1):56-68. doi: 10.1352/1934-9556-56.1.56.

PMID:
29389256
20.

Diagnostic modalities for nonalcoholic fatty liver disease, nonalcoholic steatohepatitis, and associated fibrosis.

Younossi ZM, Loomba R, Anstee QM, Rinella ME, Bugianesi E, Marchesini G, Neuschwander-Tetri BA, Serfaty L, Negro F, Caldwell SH, Ratziu V, Corey KE, Friedman SL, Abdelmalek MF, Harrison SA, Sanyal AJ, Lavine JE, Mathurin P, Charlton MR, Goodman ZD, Chalasani NP, Kowdley KV, George J, Lindor K.

Hepatology. 2018 Jul;68(1):349-360. doi: 10.1002/hep.29721.

21.

Current and future therapeutic regimens for nonalcoholic fatty liver disease and nonalcoholic steatohepatitis.

Younossi ZM, Loomba R, Rinella ME, Bugianesi E, Marchesini G, Neuschwander-Tetri BA, Serfaty L, Negro F, Caldwell SH, Ratziu V, Corey KE, Friedman SL, Abdelmalek MF, Harrison SA, Sanyal AJ, Lavine JE, Mathurin P, Charlton MR, Chalasani NP, Anstee QM, Kowdley KV, George J, Goodman ZD, Lindor K.

Hepatology. 2018 Jul;68(1):361-371. doi: 10.1002/hep.29724.

22.

Real-world cure rates for hepatitis C virus treatments that include simeprevir and/or sofosbuvir are comparable to clinical trial results.

Bichoupan K, Tandon N, Crismale JF, Hartman J, Del Bello D, Patel N, Chekuri S, Harty A, Ng M, Sigel KM, Bansal MB, Grewal P, Chang CY, Leong J, Im GY, Liu LU, Odin JA, Bach N, Friedman SL, Schiano TD, Perumalswami PV, Dieterich DT, Branch AD.

World J Virol. 2017 Nov 12;6(4):59-72. doi: 10.5501/wjv.v6.i4.59.

23.

Integrin alpha 11 in the regulation of the myofibroblast phenotype: implications for fibrotic diseases.

Bansal R, Nakagawa S, Yazdani S, van Baarlen J, Venkatesh A, Koh AP, Song WM, Goossens N, Watanabe H, Beasley MB, Powell CA, Storm G, Kaminski N, van Goor H, Friedman SL, Hoshida Y, Prakash J.

Exp Mol Med. 2017 Nov 17;49(11):e396. doi: 10.1038/emm.2017.213.

24.

SOX9 predicts progression toward cirrhosis in patients while its loss protects against liver fibrosis.

Athwal VS, Pritchett J, Llewellyn J, Martin K, Camacho E, Raza SM, Phythian-Adams A, Birchall LJ, Mullan AF, Su K, Pearmain L, Dolman G, Zaitoun AM, Friedman SL, MacDonald A, Irving WL, Guha IN, Hanley NA, Piper Hanley K.

EMBO Mol Med. 2017 Dec;9(12):1696-1710. doi: 10.15252/emmm.201707860.

25.

Case definitions for inclusion and analysis of endpoints in clinical trials for nonalcoholic steatohepatitis through the lens of regulatory science.

Siddiqui MS, Harrison SA, Abdelmalek MF, Anstee QM, Bedossa P, Castera L, Dimick-Santos L, Friedman SL, Greene K, Kleiner DE, Megnien S, Neuschwander-Tetri BA, Ratziu V, Schabel E, Miller V, Sanyal AJ; Liver Forum Case Definitions Working Group.

Hepatology. 2018 May;67(5):2001-2012. doi: 10.1002/hep.29607. Epub 2018 Feb 22.

26.

Risk factors and prevention of hepatocellular carcinoma in the era of precision medicine.

Fujiwara N, Friedman SL, Goossens N, Hoshida Y.

J Hepatol. 2018 Mar;68(3):526-549. doi: 10.1016/j.jhep.2017.09.016. Epub 2017 Oct 6. Review.

27.

A randomized, placebo-controlled trial of cenicriviroc for treatment of nonalcoholic steatohepatitis with fibrosis.

Friedman SL, Ratziu V, Harrison SA, Abdelmalek MF, Aithal GP, Caballeria J, Francque S, Farrell G, Kowdley KV, Craxi A, Simon K, Fischer L, Melchor-Khan L, Vest J, Wiens BL, Vig P, Seyedkazemi S, Goodman Z, Wong VW, Loomba R, Tacke F, Sanyal A, Lefebvre E.

Hepatology. 2018 May;67(5):1754-1767. doi: 10.1002/hep.29477. Epub 2018 Jan 29.

28.

Krüppel-like factor 6 is a transcriptional activator of autophagy in acute liver injury.

Sydor S, Manka P, Best J, Jafoui S, Sowa JP, Zoubek ME, Hernandez-Gea V, Cubero FJ, Kälsch J, Vetter D, Fiel MI, Hoshida Y, Bian CB, Nelson LJ, Moshage H, Faber KN, Paul A, Baba HA, Gerken G, Friedman SL, Canbay A, Bechmann LP.

Sci Rep. 2017 Aug 14;7(1):8119. doi: 10.1038/s41598-017-08680-w.

29.

Identification of an Immune-specific Class of Hepatocellular Carcinoma, Based on Molecular Features.

Sia D, Jiao Y, Martinez-Quetglas I, Kuchuk O, Villacorta-Martin C, Castro de Moura M, Putra J, Camprecios G, Bassaganyas L, Akers N, Losic B, Waxman S, Thung SN, Mazzaferro V, Esteller M, Friedman SL, Schwartz M, Villanueva A, Llovet JM.

Gastroenterology. 2017 Sep;153(3):812-826. doi: 10.1053/j.gastro.2017.06.007. Epub 2017 Jun 15.

30.

Serum biomarkers can predict a change in liver fibrosis 1 year after lifestyle intervention for biopsy-proven NASH.

Vilar-Gomez E, Calzadilla-Bertot L, Friedman SL, Gra-Oramas B, Gonzalez-Fabian L, Lazo-Del Vallin S, Diago M, Adams LA.

Liver Int. 2017 Dec;37(12):1887-1896. doi: 10.1111/liv.13480. Epub 2017 Jun 14.

PMID:
28544769
31.

Hepatic stellate cells as key target in liver fibrosis.

Higashi T, Friedman SL, Hoshida Y.

Adv Drug Deliv Rev. 2017 Nov 1;121:27-42. doi: 10.1016/j.addr.2017.05.007. Epub 2017 May 12. Review.

32.

Mechanisms of hepatic stellate cell activation.

Tsuchida T, Friedman SL.

Nat Rev Gastroenterol Hepatol. 2017 Jul;14(7):397-411. doi: 10.1038/nrgastro.2017.38. Epub 2017 May 10. Review.

PMID:
28487545
33.

Transcriptome-based repurposing of apigenin as a potential anti-fibrotic agent targeting hepatic stellate cells.

Hicks DF, Goossens N, Blas-García A, Tsuchida T, Wooden B, Wallace MC, Nieto N, Lade A, Redhead B, Cederbaum AI, Dudley JT, Fuchs BC, Lee YA, Hoshida Y, Friedman SL.

Sci Rep. 2017 Mar 3;7:42563. doi: 10.1038/srep42563.

34.

Devilish Effects of Taz in Nonalcoholic Steatohepatitis.

Friedman SL, Lee YA.

Cell Metab. 2016 Dec 13;24(6):771-772. doi: 10.1016/j.cmet.2016.10.006. Epub 2016 Oct 27.

35.

Liver Cancer Cell of Origin, Molecular Class, and Effects on Patient Prognosis.

Sia D, Villanueva A, Friedman SL, Llovet JM.

Gastroenterology. 2017 Mar;152(4):745-761. doi: 10.1053/j.gastro.2016.11.048. Epub 2016 Dec 30. Review.

36.

The XBP1 Arm of the Unfolded Protein Response Induces Fibrogenic Activity in Hepatic Stellate Cells Through Autophagy.

Kim RS, Hasegawa D, Goossens N, Tsuchida T, Athwal V, Sun X, Robinson CL, Bhattacharya D, Chou HI, Zhang DY, Fuchs BC, Lee Y, Hoshida Y, Friedman SL.

Sci Rep. 2016 Dec 20;6:39342. doi: 10.1038/srep39342.

37.

Molecular Liver Cancer Prevention in Cirrhosis by Organ Transcriptome Analysis and Lysophosphatidic Acid Pathway Inhibition.

Nakagawa S, Wei L, Song WM, Higashi T, Ghoshal S, Kim RS, Bian CB, Yamada S, Sun X, Venkatesh A, Goossens N, Bain G, Lauwers GY, Koh AP, El-Abtah M, Ahmad NB, Hoshida H, Erstad DJ, Gunasekaran G, Lee Y, Yu ML, Chuang WL, Dai CY, Kobayashi M, Kumada H, Beppu T, Baba H, Mahajan M, Nair VD, Lanuti M, Villanueva A, Sangiovanni A, Iavarone M, Colombo M, Llovet JM, Subramanian A, Tager AM, Friedman SL, Baumert TF, Schwarz ME, Chung RT, Tanabe KK, Zhang B, Fuchs BC, Hoshida Y; Precision Liver Cancer Prevention Consortium.

Cancer Cell. 2016 Dec 12;30(6):879-890. doi: 10.1016/j.ccell.2016.11.004.

38.

Out-of-Home Placement for Children and Adolescents With Disabilities-Addendum: Care Options for Children and Adolescents With Disabilities and Medical Complexity.

Friedman SL, Norwood KW Jr; COUNCIL ON CHILDREN WITH DISABILITIES.

Pediatrics. 2016 Dec;138(6). pii: e20163216. Review.

39.

Improvement in liver histology due to lifestyle modification is independently associated with improved kidney function in patients with non-alcoholic steatohepatitis.

Vilar-Gomez E, Calzadilla-Bertot L, Friedman SL, Gra-Oramas B, Gonzalez-Fabian L, Villa-Jimenez O, Lazo-Del Vallin S, Diago M, Adams LA, Romero-Gomez M, Chalasani N.

Aliment Pharmacol Ther. 2017 Jan;45(2):332-344. doi: 10.1111/apt.13860. Epub 2016 Nov 16.

40.

Using Big Data to Discover Diagnostics and Therapeutics for Gastrointestinal and Liver Diseases.

Wooden B, Goossens N, Hoshida Y, Friedman SL.

Gastroenterology. 2017 Jan;152(1):53-67.e3. doi: 10.1053/j.gastro.2016.09.065. Epub 2016 Oct 20. Review.

41.

Nonalcoholic Steatohepatitis Is Associated With Increased Mortality in Obese Patients Undergoing Bariatric Surgery.

Goossens N, Hoshida Y, Song WM, Jung M, Morel P, Nakagawa S, Zhang B, Frossard JL, Spahr L, Friedman SL, Negro F, Rubbia-Brandt L, Giostra E.

Clin Gastroenterol Hepatol. 2016 Nov;14(11):1619-1628. doi: 10.1016/j.cgh.2015.10.010. Epub 2015 Oct 20.

42.

PAK proteins and YAP-1 signalling downstream of integrin beta-1 in myofibroblasts promote liver fibrosis.

Martin K, Pritchett J, Llewellyn J, Mullan AF, Athwal VS, Dobie R, Harvey E, Zeef L, Farrow S, Streuli C, Henderson NC, Friedman SL, Hanley NA, Piper Hanley K.

Nat Commun. 2016 Aug 18;7:12502. doi: 10.1038/ncomms12502.

43.

A physician-scientist's wish list for the 2016 U.S. presidential candidates.

Friedman SL.

Sci Transl Med. 2016 Aug 10;8(351):351ed11. doi: 10.1126/scitranslmed.aaf9499. No abstract available.

PMID:
27510899
44.

Risk Factors for Hepatocellular Carcinoma in Cirrhotic Patients with Chronic Hepatitis B.

Zhang YQ, Peng LJ, Cao YR, Zeng ZP, Wu YJ, Shi H, Cheng SY, Wang JY, Friedman SL, Sninsky JJ, Guo JS.

Genet Test Mol Biomarkers. 2016 Sep;20(9):535-43. doi: 10.1089/gtmb.2016.0062. Epub 2016 Jul 8.

PMID:
27391584
45.

Antifibrotic Effects of the Dual CCR2/CCR5 Antagonist Cenicriviroc in Animal Models of Liver and Kidney Fibrosis.

Lefebvre E, Moyle G, Reshef R, Richman LP, Thompson M, Hong F, Chou HL, Hashiguchi T, Plato C, Poulin D, Richards T, Yoneyama H, Jenkins H, Wolfgang G, Friedman SL.

PLoS One. 2016 Jun 27;11(6):e0158156. doi: 10.1371/journal.pone.0158156. eCollection 2016.

46.

Reply.

Vilar-Gomez E, Calzadilla-Bertot L, Friedman SL, Romero-Gomez M.

Hepatology. 2016 Dec;64(6):2266-2267. doi: 10.1002/hep.28670. Epub 2016 Jul 18. No abstract available.

PMID:
27287070
47.

Late intervention with the small molecule BB3 mitigates postischemic kidney injury.

Narayan P, Duan B, Jiang K, Li J, Paka L, Yamin MA, Friedman SL, Weir MR, Goldberg ID.

Am J Physiol Renal Physiol. 2016 Aug 1;311(2):F352-61. doi: 10.1152/ajprenal.00455.2015. Epub 2016 Jun 1.

48.

The Transcriptional Activator Krüppel-like Factor-6 Is Required for CNS Myelination.

Laitman BM, Asp L, Mariani JN, Zhang J, Liu J, Sawai S, Chapouly C, Horng S, Kramer EG, Mitiku N, Loo H, Burlant N, Pedre X, Hara Y, Nudelman G, Zaslavsky E, Lee YM, Braun DA, Lu QR, Narla G, Raine CS, Friedman SL, Casaccia P, John GR.

PLoS Biol. 2016 May 23;14(5):e1002467. doi: 10.1371/journal.pbio.1002467. eCollection 2016 May.

49.

Interleukin-15 receptor α on hepatic stellate cells regulates hepatic fibrogenesis in mice.

Jiao J, Ooka K, Fey H, Fiel MI, Rahmman AH, Kojima K, Hoshida Y, Chen X, de Paula T, Vetter D, Sastre D, Lee KH, Lee Y, Bansal M, Friedman SL, Merad M, Aloman C.

J Hepatol. 2016 Aug;65(2):344-353. doi: 10.1016/j.jhep.2016.04.020. Epub 2016 May 3.

50.

The LATS2 tumor suppressor inhibits SREBP and suppresses hepatic cholesterol accumulation.

Aylon Y, Gershoni A, Rotkopf R, Biton IE, Porat Z, Koh AP, Sun X, Lee Y, Fiel MI, Hoshida Y, Friedman SL, Johnson RL, Oren M.

Genes Dev. 2016 Apr 1;30(7):786-97. doi: 10.1101/gad.274167.115. Epub 2016 Mar 24.

Supplemental Content

Loading ...
Support Center